6th iPSC Drug Development Summit
2026-09-09 - 2026-09-10 | Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA, 02128, United States
As iPSC therapies transition from promise to clinical reality, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists, CMC experts, and decision-makers, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization.
This year’s agenda is designed to address the most pressing challenges across the iPSC pipeline, with a sharp focus on scalability, manufacturability, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks, covering preclinical development and process development & CMC, including genome editing strategies, donor and cell line selection, functional quality control, and GMP-ready manufacturing approaches.
The summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease, diabetes, oncology, and ocular disorders.
Speaker highlights include:

Yanzheng Liu, Senior Director, Aspen Neuroscience
Rachel Knopp and Yongting Wang, Astellas Pharma
William Hendriks, Director of PSC Biology, BlueRock Therapeutics
Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics
Alex Ng, Chief Scientific Officer, GC Therapeutics
Marcella Garita-Hernandez, Head of iPS Core, Harvard Medical School

With contributions from organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks.
Designed for professionals actively building iPSC pipelines, the summit offers an end-to-end view of the field, alongside collaborative networking with peers across biopharma, academia, and investment. From optimizing early discovery decisions to ensuring commercial readiness, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies.
Find out more here: https://ter.li/japojzin
This meeting is free to attend* for biopharma and academics.

9th Neuropsychiatric Drug Development Summit
2026-09-15 - 2026-09-17 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry, this summit brings together senior decision‑makers to redefine how the industry translates science into successful, patient‑centred therapies.
Across discovery, translational science, and clinical development, the agenda showcases the most promising advances in the field — from psychedelics, muscarinics, orexins, and novel neuroplasticity approaches to cutting‑edge translational tools such as EEG, digital and speech biomarkers, sleep endpoints, and smarter patient stratification. Attendees will gain practical insights into overcoming placebo response, heterogeneity, and late‑stage failure through biology‑driven, regulatory‑ready strategies.
Designed for meaningful connection and collaboration, the summit offers an intimate, highly interactive environment to exchange data, challenge assumptions, and build partnerships with peers tackling depression, schizophrenia, bipolar disorder, anxiety, PTSD, and addiction. Join the global community accelerating the next era of precision psychiatry.
Find out more today – https://ter.li/rt2cakk3

COPD Drug Development Summit
2026-09-15 - 2026-09-17 | Homewood Suites by Hilton Boston Seaport District, 670 Summer Street, Boston, MA, 02210, United States
The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics
The COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease.
With the approval of the first biologic therapy marking a historic turning point, COPD R&D is entering a new era, one defined by deeper biological understanding, more precise patient segmentation, and a renewed push toward disease‑modifying treatments.
This summit convenes leading scientists, clinicians, regulatory experts, and biotech innovators to address the scientific and operational barriers that have long constrained progress.
Over three days, attendees will explore the most urgent and promising areas shaping the future of COPD therapeutics.
Core themes include novel target discovery, translational alignment, and smarter clinical trial design that reflects the heterogeneity of COPD endotypes.
The program also examines the limitations of traditional endpoints such as exacerbations and FEV₁, highlighting next‑generation measures, including imaging‑based progression tools, AI‑enabled assessment, and biomarkers capable of capturing early disease activity and therapeutic impact.
With 65+ industry leaders and 16+ expert speakers from organisations including Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Generate Biomedicines, and Ethris, the summit offers a uniquely concentrated environment for scientific exchange and partnership building.
Participants will engage in 7+ hours of structured networking, panel discussions, and case‑study‑driven sessions that illuminate both the opportunities and the remaining challenges in COPD drug development.
Designed for discovery scientists, translational researchers, clinical developers, regulatory strategists, and biotech executives, this event provides a rare chance to shape the next chapter of COPD innovation.
As the field moves toward more personalised, mechanism‑driven approaches, the COPD Drug Development Summit serves as a critical platform for aligning science, strategy, and regulatory confidence to deliver better outcomes for millions of patients worldwide.
Register now: https://ter.li/kvevwxqk

11th CAR-TCR Summit
2026-09-15 - 2026-09-17 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone, but by smarter biological design, delivery strategies and manufacturing breakthroughs to lower COGs, expand patient access and secure commercial viability.
With this, the 11th CAR-TCR Summit is making its hotly anticipated return to Boston, September 15-17.
View the agenda here.
Crafted in collaboration with industry veterans and spanning four tracks across the entire development life cycle, the program offers a clear, strategic view of the next era of cell therapy. Expect first hand insight into cutting-edge in vivo and next generation CAR and TCR innovations, hear unpublished clinical data across emerging indications, and learn from real world automated manufacturing case studies shaping commercial readiness.
Beyond the science, you’ll gain direct access to investors to align on where capital and strategic partnerships are moving next, complemented by high-value networking with C-suite executives and academic KOLs to safegaurd every stage of your cell therapy development pipeline.
If you’re committed to driving the innovation and commercial readiness needed to make CAR-T therapies safer, more effective, scalable, and accessible to the patients who need them most, then this is the meeting for you.
Download your copy of the agenda.

Measuring Patient Engagement Summit Europe
2026-09-15 - 2026-09-17 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
The Measuring Patient Engagement Summit Europe is the leading industry forum dedicated to supporting biopharma in quantifying and demonstrating the true impact of patient engagement. As regulatory expectations rise and internal stakeholders demand a clearer return on investment, the need for robust, evidence-based frameworks has never been greater. This three-day summit brings together over 70 senior leaders across patient engagement, advocacy, insights, experience, and medical affairs to address one of the industry’s most pressing challenges – moving from activity-based reporting to measurable impact and defensible KPIs.
Designed to bridge the gap between strategy and proof, the event focuses on establishing credible, comparable, and actionable metrics that demonstrate how patient engagement influences decision-making across the product lifecycle. Attendees will gain practical insights into how patient input drives improvements in protocol design, accelerates clinical trial recruitment, supports regulatory alignment, and strengthens market access outcomes.
Through a combination of real-world case studies, expert-led discussions, and collaborative sessions, the summit offers a unique opportunity to benchmark approaches, co-develop frameworks, and create a shared language of value recognised by regulators, payers, and patients alike. By equipping participants with proven methodologies and peer-tested tools, the event empowers organisations to embed patient engagement as a strategic, data-driven driver of innovation – ensuring its impact is both defensible and impossible to ignore.
Agenda Highlights Include:

Moving beyond activity-based KPIs to define and measure meaningful patient engagement impact
Demonstrating measurable outcomes across clinical trial design, recruitment, and retention
Quantifying the influence of patient insights on regulatory, payer, and market access decisions
Developing credible and standardised frameworks to benchmark engagement success
Translating patient experience data into tangible clinical and commercial value
Aligning patient engagement strategies with ESG and broader organisational priorities
Building a common language of value recognised across industry stakeholders

This summit provides a critical platform for advancing the measurement of patient engagement, enabling organisations to shift from intention to evidence and truly demonstrate the value of patient-centric approaches.
Get your copy of the agenda now to learn more: https://ter.li/fy580o27.

4th TRP Supply Chain & Manufacturing Summit
2026-09-15 - 2026-09-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
4th TRP Supply Chain & Manufacturing Summit (September 15–17, 2026 | Boston, MA)
Radiopharmaceuticals are entering a defining stage of development. As clinical programs advance into Phase II, Phase III, and commercial readiness, the ability to manufacture and deliver therapies reliably has become one of the industry’s greatest challenges. Rising demand for isotopes, infrastructure constraints, workforce shortages, evolving regulatory expectations, and the unique realities of short half-life materials are placing unprecedented pressure on supply chain and manufacturing teams.
The 4th TRP Supply Chain & Manufacturing Summit is the only industry-focused forum dedicated exclusively to the supply chain, manufacturing, CMC, quality, and logistics challenges impacting radiopharmaceutical development. Bringing together 60+ senior leaders from pharma, biotech, CDMOs, isotope providers, and logistics organizations, the meeting is designed to help attendees overcome the operational bottlenecks that stand between scientific breakthroughs and patient delivery.
Across two conference days and interactive workshops, attendees will gain practical insights to:

Strengthen isotope supply resilience across established and emerging alpha and beta emitters
Scale manufacturing operations to support late-stage clinical trials and commercialization
Evaluate build vs. buy manufacturing strategies and optimize CDMO partnerships
Implement automation and digital solutions to improve consistency, throughput, and compliance
Optimize logistics and distribution networks for time-sensitive radiopharmaceutical therapies
Navigate evolving regulatory expectations with greater confidence and preparedness

Featuring experts from AstraZeneca, Bayer, Telix Pharmaceuticals, Cellectar Biosciences, Ratio Therapeutics, Convergent Therapeutics, Molecular Partners AG, Purdue University, and the University of Alabama at Birmingham, the summit delivers real-world case studies and practical strategies from organizations actively addressing today’s most pressing supply chain and manufacturing challenges.
With 10+ hours of dedicated networking, attendees can benchmark approaches, exchange lessons learned, and build the partnerships needed to move radiopharmaceutical therapies from bench to patient reliably and at scale.

5th Lipid Nanoparticles Development Summit Europe
2026-09-23 - 2026-09-24 | Dorint Kurfürstendamm Berlin, Augsburger Strasse 41, Berlin, 10789, Germany
The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23rd – 24th September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA, DNA and gene editing therapies. With interactive discussions and real-world case studies, this event delivers actionable insights to accelerate safe, targeted and clinically viable delivery platforms.
To learn more and register online, please visit: https://ter.li/mft1fbw0

7th Genome Editing Therapeutics Summit
2026-09-28 - 2026-09-30 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options.

But intent and support alone won’t get these therapies to patients. Developmental, manufacturing, and regulatory challenges still stand between the lab and the patients waiting.
That’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting.
Join R&D, preclinical, translational, regulatory, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most?
Don’t miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.
What’s New in 2026?
In 2026, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy, the decisions made now will determine which assets reach patients.
At this year’s summit you will:

Delve into extrahepatic delivery strategies to widen your technology across multiple disease indications

Learn from clinical companies building robust IND packages to fast-track development

Evaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile

Explore the Brand-New Agenda to Discover:

3 days of content to find the sessions your program needs most

50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage

80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers

64% in vivo & 36% ex vivo agenda to fit your route of delivery

2 brand-new workshops

View the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy

10th IPF Summit
2026-09-29 - 2026-10-01 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
10th Anniversary Edition of the IPF Summit –
September 29 – October 1, 2026 | Boston, MA
For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher.
Following a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb, United Therapeutics, and Boehringer Ingelheim, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge, the question is no longer can we develop treatments, but how to do so smarter, faster, and with meaningful differentiation.
The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this challenge head-on.
Bringing together 150+ experts across discovery, translational science, and clinical development, from organizations including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, and many more, the summit offers a uniquely integrated view of the scientific, clinical, and strategic decisions shaping the next decade of IPF innovation.
Across dedicated content tracks, dive into emerging biology and novel targets to unlock new therapeutic avenues, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape
New for 2026 includes a dedicated ILD & PPF Focus Day, designed to unpack the complexity of fibrotic lung diseases beyond IPF, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.
With 8+ hours of networking in an intentionally intimate setting, the summit is built for honest, high-value discussions, giving you direct access to the people shaping the future of pulmonary fibrosis drug development.
Whether you’re advancing early discovery, translating assets into the clinic, or positioning therapies in a crowded market, this is where the field aligns on what success now looks like, and how to achieve it.
Find out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk

Designing the AI-Enabled Life Sciences Workforce Summit Europe
2026-09-29 - 2026-09-30 | Essential by Dorint Basel City, Schönaustrasse 10, Switzerland, Basel, 4058, Switzerland
AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution.
The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built specifically for senior HR leaders to tackle this challenge head-on. Bringing together CHROs and workforce transformation leaders from leading drug developers, this is where strategy meets execution – and where organisations learn how to redesign work, skills, and operating models to deliver measurable business impact at scale.
At a time when life science organisations must drive productivity, innovation, and growth without increasing headcount, this event provides the practical frameworks, peer insights, and proven strategies you need to move faster with confidence.
This is not a conference about AI trends – it is a working forum focused on how life sciences organisations are redesigning work, workforce strategy, and operating models in response to AI.
Across two highly interactive days, you will learn directly from leaders who are actively transforming their organisations – moving beyond pilots to deliver enterprise-wide impact. Through a unique blend of case studies, discussion, and working sessions, you will leave not only inspired but equipped with clear, actionable next steps.
For more information and to register online, please click here.

5th mRNA Process Development & CMC Summit 2026
2026-09-29 - 2026-10-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy.
As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA therapeutics, including senior decision-makers from GSK, Eli Lilly, Centivax, Circurna, Sanofi, BioNTech and more!
From scaling processes and strengthening analytical capabilities to navigating global expansion and clinical readiness, this is where the industry’s most pressing CMC challenges are tackled head-on.
Find out more: https://ter.li/peoi4f1e

16th World Clinical Biomarkers & Companion Diagnostics Summit
2026-10-05 - 2026-10-08 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly.
Building on this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall, uniting 850+ senior stakeholders in the common goal of advancing timely, accessible and affordable precision medicine to patients in need.
Be the first to access our new event program: https://ter.li/5c0adwgh
Join industry-leading peers from biopharma, diagnostics, testing labs, and regulatory bodies, to unpack fit-for-purpose CDx strategies, spark new co-development partnerships, discover cutting-edge genomic sequencing, pathology, multi-omic, single cell and multimodal innovations.
This year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development.

Biomarker Discovery & Translation
Clinical & CDx Development
Rx-Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers (BRAND-NEW)
Multimodal & AI‑Enabled Endpoints (BRAND-NEW)

Grasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement.
Together let’s translate promising precision medicine into scalable, equitable drug-diagnostic therapies for patients across oncology, neurological, autoimmune, rare and chronic diseases.
Sign up today: https://ter.li/0jb66uvu
Registration is FREE* for drug developers and researchers.
*Subject to terms and conditions visit the website to learn more.

17th World ADC San Diego
2026-10-12 - 2026-10-15 | Town & Country San Diego, 500 Hotel Circle, North San Diego, San Diego, CA, 92108, United States
Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.
With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments.
Uniting 1,300 industry senior enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs, World ADC San Diego is the place to discuss, debate and advance the future of ADC development.
Featuring 170+ senior presenters, a snapshot of the 2026 speaker faculty includes:

Suzanne Edavettal, Vice President, Research & Head, Protein Therapeutics, Amgen
Vinod Bulusu, Executive Director, Product Stewardship Lead, AstraZeneca
Giorgia Vicentini, Vice President, Global Program Lead, Oncology, Bristol Myers Squibb
Ronald Fleming, Executive Director, Clinical Development, Daiichi Sankyo
Gail Lewis, Distinguished Scientist, Discovery Oncology, Genentech
Min Hu, Senior Vice President, Discovery, Innovent Biologics
Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics
Jeffrey Settleman, Chief Scientific Officer, Oncology R&D, Pfizer
Dominik Schumacher, Chief Executive Officer, Tubulis
Rita Nanda, Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/Oncology, University of Chicago

View the full list of speaking companies: https://ter.li/xsz013cs
If you want to stay competitive in the field, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.

5th Operationalise: Early Access Programmes Summit Europe
2026-10-19 - 2026-10-21 | Park Plaza Victoria London, 239 Vauxhall Bridge Road Pimlico, London, SW1V 1EQ, United Kingdom
Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets.
The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift, reimbursement timelines extend, and programmes scale globally, organisations must make more decisions, earlier, and with greater consequence.
This is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs, Access, Regulatory, Clinical Operations, and Supply to share how programmes are being designed, adapted, and delivered in practice.
Whether you are building your first programme, scaling across regions, or managing a global access portfolio, this is your opportunity to benchmark your approach, challenge your assumptions, and leave with the insight needed to make smarter decisions and deliver earlier, sustainable access for patients in 2026 and beyond.
For more information and to register online, please click here.

4th Covalent Drug Discovery & Development Summit
2026-10-20 - 2026-10-22 | Hampton Inn Boston Seaport District, 670 Summer St, Boston, MA, 02210, United States
4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA)
Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology.
As the field evolves, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes.
The 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists, chemical biologists, translational scientists, and early clinical leaders, the meeting delivers a truly end-to-end perspective across covalent drug development, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs.
Across two conference days and interactive workshops, attendees will gain practical, actionable insights to:

Design safer, more selective covalent compounds using novel warheads and structure-guided approaches
De-risk development through advanced toxicity, reactivity, and safety assessment strategies
Integrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions
Expand the druggable space by targeting new residues and previously undruggable biology

With case studies spanning AI-driven discovery, chemoproteomics, kinetic assays, and translational workflows, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies.
Bringing together 80+ senior leaders from pharma, biotech, and academia, this is a highly curated environment for deep technical exchange, collaboration, and real-world problem solving.
Whether you are optimizing discovery, scaling translational strategy, or preparing for the clinic, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.

9th TPD & Induced Proximity Summit
2026-10-26 - 2026-10-29 | The Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, MA, 02210, United States
After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone.
However, following the risk-averse funding environment of 2025, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it is designed to help you discover the best novel targets, optimize your degrader profile, and accelerate your pipelines to the clinic and beyond.
View the full event guide.

9th RNA-Targeted Drug Discovery & Development Summit
2026-11-10 - 2026-11-12 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics.
As momentum continues to build across the field, driven by recent clinical progress and increasing investment in RNA-targeted approaches, the summit will explore the latest advances in direct RNA binding, splice modulation, RNA degradation, covalent translation inhibition, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology, rare genetic diseases and neurodegenerative disorders.
A refreshed 2026 agenda will feature expert-led presentations, case studies, panel discussions and interactive workshops covering functional RNA target selection, structure-guided design, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches, measuring selectivity, validating targets and accelerating translation from discovery into clinical development.
The summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers, including representatives from PTC Therapeutics, AstraZeneca, Sanofi, ReviR Therapeutics, Remix Therapeutics, Arrakis Therapeutics, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions, attendees will connect with the scientists, innovators and decision-makers shaping the future of RNA-targeted medicines.
Whether you are focused on RNA biology, medicinal chemistry, drug discovery, translational research or therapeutic development, this summit offers an unparalleled opportunity to access cutting-edge data, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.
